MedInCell Shares Drop 2.84% But Still Up 54% Year-Over-Year
Shares of the biotech company based in Montpellier fell early in the week, in a declining Parisian market. The CAC 40 is down 0.51% during the session and the SBF 120 loses 0.40%. However, the stock remains up over 54% for the year.
A Measured Decline in a Pressured Parisian Market
MedInCell falls 2.84% to €23.98 at midday, after closing at €24.68 in the last session. This movement continues the 3.55% decline observed last Thursday, April 30, which itself followed a rebound of 5.51% the day before. Over seven days, the performance remains positive at 3.54%. The session context is heavy. The CAC 40 is at 8,073.71 points (-0.51%) and the SBF 120 at 6,133.83 points (-0.40%). In the background, the ECB kept its key interest rates unchanged on April 30, signaling an intensification of upward risks on inflation and downward risks on growth, linked to the conflict in the Middle East and rising energy prices. Brent is trading around $108.36 a barrel. These macro elements remain a backdrop to the session, with no direct link established with the biotech's movement.
A Busy Schedule with the R&D Day on May 12 in Sight
The stock price moves in the upper part of the Bollinger Bands, at 66% of the width, between €21.31 and €25.35. The resistance at €25.12 remains immediately close, just over 4% from the current price. The RSI at 49 indicates a balance between buyers and sellers, without excess in either direction. The stock has fallen below its MM200 at €24.03; it had moved above this level at the beginning of April but had already lost this level by mid-April. The short-term agenda is packed. The company will hold a live R&D day on May 12, 2026, before the publication of annual results (fiscal year April 2025 - March 2026) on June 16. At the last semi-annual publication (April-September 2025), MedInCell indicated it expected an acceleration of revenues in the coming years with olanzapine LAI, for which the NDA application has been filed. Teva has also raised its 2025 net sales forecast for UZEDY® from $160 million to $190-200 million. The May 12 event is the next scheduled point by the company.
